{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:04Z","timestamp":1787003644526,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90419-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:39:12Z","timestamp":1740022752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["METTL3 promotes the progression of non-alcoholic fatty liver disease by mediating m6A methylation of FAS"],"prefix":"10.1038","volume":"15","author":[{"given":"Qunhua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"1","key":"90419_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels, S. et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22 (1), 63 (2022).","journal-title":"BMC Endocr. Disord"},{"issue":"10290","key":"90419_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397 (10290), 2212\u20132224 (2021).","journal-title":"Lancet"},{"issue":"6","key":"90419_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jdi.13756","volume":"13","author":"CH Lee","year":"2022","unstructured":"Lee, C. H., Lui, D. T. & Lam, K. S. Non-alcoholic fatty liver disease and type 2 diabetes: an update. J. Diabetes Investig. 13 (6), 930\u2013940 (2022).","journal-title":"J. Diabetes Investig."},{"issue":"6","key":"90419_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s12072-022-10395-8","volume":"16","author":"S Man","year":"2022","unstructured":"Man, S. et al. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol. Int. 16 (6), 1412\u20131423 (2022).","journal-title":"Hepatol. Int."},{"key":"90419_CR5","doi-asserted-by":"publisher","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","volume":"13","author":"L Rong","year":"2022","unstructured":"Rong, L. et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol. (Lausanne). 13, 1087260 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"90419_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro, R. & Trauner, M. Current treatment of non-alcoholic fatty liver disease. J. Intern. Med. 292 (2), 190\u2013204 (2022).","journal-title":"J. Intern. Med."},{"key":"90419_CR7","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64 (6), 1388\u20131402 (2016).","DOI":"10.1016\/j.jhep.2015.11.004"},{"issue":"3","key":"90419_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2023.01.006","volume":"83","author":"E Sendinc","year":"2023","unstructured":"Sendinc, E. & Shi, Y. RNA m6A methylation across the transcriptome. Mol. Cell. 83 (3), 428\u2013441 (2023).","journal-title":"Mol. Cell."},{"issue":"8","key":"90419_CR9","first-page":"785","volume":"46","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Abnormal m6A modification in non-alcoholic fatty liver disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 46 (8), 785\u2013792 (2021).","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"6","key":"90419_CR10","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.ymthe.2022.02.021","volume":"30","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol. Ther. 30 (6), 2342\u20132353 (2022).","journal-title":"Mol. Ther."},{"key":"90419_CR11","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.phrs.2021.105937","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang, B. et al. RNA methylation and cancer treatment. Pharmacol. Res. 174, 105937 (2021).","journal-title":"Pharmacol. Res."},{"issue":"11","key":"90419_CR12","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.drudis.2021.06.004","volume":"26","author":"S Garbo","year":"2021","unstructured":"Garbo, S., Zwergel, C. & Battistelli, C. m6A RNA methylation and beyond - the epigenetic machinery and potential treatment options. Drug Discov. Today 26 (11), 2559\u20132574 (2021).","journal-title":"Drug Discov. Today"},{"issue":"2","key":"90419_CR13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ymthe.2021.09.016","volume":"30","author":"Z Peng","year":"2022","unstructured":"Peng, Z. et al. METTL3-m(6)A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. Mol. Ther. 30 (2), 932\u2013946 (2022).","journal-title":"Mol. Ther."},{"issue":"15","key":"90419_CR14","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1021\/acs.chemrev.1c00147","volume":"121","author":"P Paiva","year":"2021","unstructured":"Paiva, P. et al. Animal fatty acid synthase: a chemical nanofactory. Chem. Rev. 121 (15), 9502\u20139553 (2021).","journal-title":"Chem. Rev."},{"issue":"4","key":"90419_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","volume":"21","author":"B Batchuluun","year":"2022","unstructured":"Batchuluun, B., Pinkosky, S. L. & Steinberg, G. R. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat. Rev. Drug Discov. 21 (4), 283\u2013305 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5894","key":"90419_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.1161269","volume":"321","author":"T Maier","year":"2008","unstructured":"Maier, T., Leibundgut, M. & Ban, N. The crystal structure of a mammalian fatty acid synthase. Science 321 (5894), 1315\u20131322 (2008).","journal-title":"Science"},{"issue":"3","key":"90419_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith, G. I. et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J. Clin. Invest. 130 (3), 1453\u20131460 (2020).","journal-title":"J. Clin. Invest."},{"key":"90419_CR18","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren, J. & Scheja, L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol. Metab. 50, 101238 (2021).","journal-title":"Mol. Metab."},{"issue":"11","key":"90419_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","volume":"38","author":"N Higuchi","year":"2008","unstructured":"Higuchi, N. et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38 (11), 1122\u20131129 (2008).","journal-title":"Hepatol. Res."},{"issue":"2","key":"90419_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.tem.2022.12.006","volume":"34","author":"X Zhu","year":"2023","unstructured":"Zhu, X. et al. N6-methyladenosine in macrophage function: a novel target for metabolic diseases. Trends Endocrinol. Metab. 34 (2), 66\u201384 (2023).","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"90419_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.gpb.2020.06.003","volume":"18","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. M(6)a regulates Liver Metabolic disorders and Hepatogenous Diabetes. Genomics Proteom. Bioinf. 18 (4), 371\u2013383 (2020).","journal-title":"Genomics Proteom. Bioinf."},{"issue":"6","key":"90419_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41401-021-00786-2","volume":"43","author":"YK Wu","year":"2022","unstructured":"Wu, Y. K. et al. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21\/FGFR1 signaling pathway. Acta Pharmacol. Sin. 43 (6), 1473\u20131483 (2022).","journal-title":"Acta Pharmacol. Sin"},{"issue":"2","key":"90419_CR23","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.xpro.2020.100086","volume":"1","author":"M Charni-Natan","year":"2020","unstructured":"Charni-Natan, M. & Goldstein, I. Protocol for primary mouse hepatocyte isolation. STAR. Protoc. 1 (2), 100086 (2020).","journal-title":"STAR. Protoc."},{"issue":"1","key":"90419_CR24","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.1080\/21655979.2021.1960463","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA mir-380-5p with lipoprotein-related protein LRP2. Bioengineered 12 (1), 6738\u20136747 (2021).","journal-title":"Bioengineered"},{"issue":"11","key":"90419_CR25","doi-asserted-by":"publisher","first-page":"e21846","DOI":"10.1016\/j.heliyon.2023.e21846","volume":"9","author":"M Zheng","year":"2023","unstructured":"Zheng, M. et al. Korean red ginseng formula attenuates non-alcoholic fatty liver disease in oleic acid-induced HepG2 cells and high-fat diet-induced rats. Heliyon 9 (11), e21846 (2023).","journal-title":"Heliyon"},{"issue":"1","key":"90419_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. The role of m6A modification in the biological functions and diseases. Signal. Transduct. Target. Ther. 6 (1), 74 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6","key":"90419_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2174\/1389203717666160627082444","volume":"18","author":"X Wang","year":"2017","unstructured":"Wang, X. & Wang, Y. From histones to RNA: role of methylation in Signal Proteins Involved in Adipogenesis. Curr. Protein Pept. Sci. 18 (6), 589\u2013598 (2017).","journal-title":"Curr. Protein Pept. Sci."},{"issue":"11","key":"90419_CR28","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2217\/epi-2019-0009","volume":"11","author":"Z Luo","year":"2019","unstructured":"Luo, Z. et al. Comprehensive analysis of differences of N(6)-methyladenosine RNA methylomes between high-fat-fed and normal mouse livers. Epigenomics 11 (11), 1267\u20131282 (2019).","journal-title":"Epigenomics"},{"key":"90419_CR29","doi-asserted-by":"publisher","first-page":"973116","DOI":"10.3389\/fphar.2022.973116","volume":"13","author":"W Cheng","year":"2022","unstructured":"Cheng, W. et al. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC. Front. Pharmacol. 13, 973116 (2022).","journal-title":"Front. Pharmacol."},{"issue":"6","key":"90419_CR30","doi-asserted-by":"publisher","first-page":"109968","DOI":"10.1016\/j.celrep.2021.109968","volume":"37","author":"Y Qin","year":"2021","unstructured":"Qin, Y. et al. M(6)a mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell. Rep. 37 (6), 109968 (2021).","journal-title":"Cell. Rep."},{"key":"90419_CR31","doi-asserted-by":"publisher","first-page":"113367","DOI":"10.1016\/j.biopha.2022.113367","volume":"153","author":"R Xu","year":"2022","unstructured":"Xu, R. et al. The methyltransferase METTL3-mediated fatty acid metabolism revealed the mechanism of cinnamaldehyde on alleviating steatosis. Biomed. Pharmacother. 153, 113367 (2022).","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"90419_CR32","doi-asserted-by":"publisher","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4 (6), 100479 (2022).","journal-title":"JHEP Rep."},{"key":"90419_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.phymed.2018.09.006","volume":"53","author":"R Dong","year":"2019","unstructured":"Dong, R. et al. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. Phytomedicine 53, 134\u2013142 (2019).","journal-title":"Phytomedicine"},{"issue":"2","key":"90419_CR34","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/jcb.26317","volume":"119","author":"X Wang","year":"2018","unstructured":"Wang, X. Down-regulation of lncRNA-NEAT1 alleviated the non-alcoholic fatty liver disease via mTOR\/S6K1 signaling pathway. J. Cell. Biochem. 119 (2), 1567\u20131574 (2018).","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"90419_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An, Y. & Duan, H. The role of m6A RNA methylation in cancer metabolism. Mol. Cancer 21 (1), 14 (2022).","journal-title":"Mol. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90419-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90419-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90419-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:39:16Z","timestamp":1740022756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90419-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90419"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90419-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Affiliated Hospital of Chengdu University. This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. All experiments were performed in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"6162"}}